Yasuhito Fujisaka

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011 · 658 citations

Cetuximab Sensitivity, Oncology, Erbb2 Signaling +15

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

Jun Sato, Miyako Satouchi, Shoichi Itoh et al. · The Lancet Oncology · 2020 · 203 citations

Oncology, Metastatic Thymic Carcinoma, Metronomic Therapy +5

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

Tomohide Tamura, Hironobu Minami, Yasuhide Yamada et al. · Journal of Thoracic Oncology · 2006 · 130 citations · Full text

Dose-escalation Study, Medicine, Malignant Tumors +8

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

Noboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka et al. · Cancer Chemotherapy and Pharmacology · 2007 · 80 citations

Oncology, Solid Tumors, Medicine +7